Eldred Rock Partners’s Novartis NVS Stock Holding History

Eldred Rock Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6M	Sell	80,627 -141	-0.2%	-$21.1K	2.72%	20
2026 Q1	$12.3M	Sell	80,768 -781	-1%	-$120K	3.14%	18
2025 Q4	$11.2M	Sell	81,549 -9,204	-10%	-$1.21M	2.92%	20
2025 Q3	$11.6M	Buy	90,753 +9,871	+12%	+$1.2M	2.9%	18
2025 Q2	$9.79M	Buy	80,882 +47	+0.1%	+$5.3K	2.97%	19
2025 Q1	$9.03M	Buy	80,835 +20,184	+33%	+$2.15M	2.76%	23
2024 Q4	$5.9M	Buy	60,651 +108	+0.2%	+$11.5K	2.03%	26
2024 Q3	$6.96M	Buy	60,543 +32,816	+118%	+$3.72M	2.33%	27
2024 Q2	$2.95M	Buy	27,727 +13,348	+93%	+$1.34M	1.23%	26
2024 Q1	$1.39M	Buy	14,379 +588	+4%	+$60.3K	0.76%	24
2023 Q4	$1.39M	Buy	+13,791	New	+$1.33M	0.89%	22

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Eldred Rock Partners's NVS Position: Q2 2026 in Review

Eldred Rock Partners reduced its Novartis (NVS) stake by 0.17% in Q2 2026, selling an estimated $21.1K and leaving 80,627 shares worth $12.6M. The position accounts for 2.72% of the portfolio, ranked #20.

Eldred Rock Partners first reported a position in NVS in Q4 2023 and has held it in 11 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Eldred Rock Partners held 80,627 shares of Novartis worth $12.6M as of Q2 2026.
Eldred Rock Partners sold 141 Novartis shares in Q2 2026, an estimated $21.1K.
Novartis made up 2.72% of Eldred Rock Partners's portfolio in Q2 2026, its #20 holding.
Eldred Rock Partners first reported a position in Novartis in Q4 2023 and has held it in 11 quarters since.
1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Eldred Rock Partners's 13F filing for Q2 2026, filed 8 Jul 2026.